Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen developed Contrave® (naltrexone HCl and bupropion HCl extended release), which is approved in the United States and is being commercialized there by the companys North American partner, Takeda Pharmaceuticals. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged release). Orexigen's strategy for Contrave/ Mysimba is to pursue marketing authorizations worldwide and pharmaceutical partnerships for global commercialization. Further information about the Company can be found at www.orexigen.com.